A top federal health official urged the creation of dedicated men’s health centers during a public discussion on testosterone replacement therapy, calling the situation a “men’s health crisis.” The session, convened by the U.S. Food and Drug Administration, also drew calls from several speakers to ease access to hormones for men who report fatigue, low mood, and other symptoms linked to low testosterone. The exchange signaled growing pressure on regulators and clinicians to rethink care for aging men and those with confirmed hormone disorders.
Why Testosterone Therapy Is Under Review
Testosterone therapy is approved for men with low levels due to specific medical conditions that impair the testes or pituitary gland. For years, doctors and regulators have debated if it should be used for age-related declines. Concerns about heart and stroke risk led the FDA in 2015 to limit marketing and strengthen warnings.
New data have complicated that picture. A large study published in 2023 found no increase in major cardiac events among men on testosterone compared with placebo, though it did report higher rates of some problems, including atrial fibrillation and blood clots. The FDA later updated labels to highlight increases in blood pressure across products. The result is a split: some clinicians see room for wider use with careful screening, while others remain cautious.
Calls for Dedicated Men’s Health Centers
One senior official framed the challenge in stark terms, urging a focused response.
We need special health centers to address a “men’s health crisis.”
Supporters say such centers could offer one-stop access to hormone testing, primary care, mental health services, fertility counseling, and lifestyle programs. They argue many men avoid routine care and present late with chronic conditions. Organizing services under one roof, they say, could improve screening for low testosterone and other issues, while reducing risky self-treatment.
Critics worry about overprescribing. They caution that clinics built around a single therapy can bias decisions and might crowd out non-drug options like sleep treatment, weight loss, or depression care. They also point to gaps in evidence on long-term outcomes in older men without a clear underlying hormone disorder.
Push to Ease Access Meets Safety Concerns
Several participants urged easier access to treatment, citing long waits for specialists and uneven insurance coverage for lab testing. They said many men struggle to get evaluated for symptoms that erode work, relationships, and quality of life.
Others urged guardrails. Testosterone can raise red blood cell counts, affect fertility, and worsen undiagnosed prostate conditions. It may interact with other drugs and can drive up blood pressure. Better access, these voices argued, should come with standardized screening, informed consent, and routine follow-up.
- Screening: Morning testosterone measured twice, plus symptom review.
- Safety checks: Blood counts, prostate evaluation as appropriate, blood pressure monitoring.
- Alternatives: Address sleep apnea, obesity, depression, and medication side effects.
Telehealth Growth and the Risk of Misuse
Telehealth has expanded the testosterone market, offering quick visits and home delivery. Advocates say this reduces stigma and reaches rural patients. But rapid prescribing based on limited testing has raised alarms. Experts at the session warned that inconsistent lab standards and infrequent follow-up can lead to missed side effects or dosing errors.
There is also a gray zone between medical therapy and performance enhancement. Anabolic steroid misuse remains a concern, and easier hormone access could blur lines if verification is weak. Speakers urged clearer rules for online clinics and better education for patients who might seek therapy for athletic or cosmetic reasons.
What Changes Might Come Next
The discussion pointed to several possible steps. Participants mentioned integrated men’s clinics with primary care leadership, stronger evidence-based protocols, and clearer coverage policies for testing and follow-up. Some called for public education on symptoms, risks, and realistic goals from treatment.
Regulators could also seek more data on long-term safety in older men and in those with metabolic disease. Researchers have asked for studies that track mood, sleep, sexual function, and cardiovascular markers over several years. Health systems may pilot care pathways that combine hormone therapy with weight management and mental health support.
The session revealed a shared goal: better outcomes for men who are often slow to seek care. But it also showed the tension between faster access and safe, proven use. The idea of dedicated centers gained fresh attention, and the push to streamline care is likely to grow. The FDA’s next steps, along with insurer policies and new research, will shape how far testosterone therapy moves from specialist corners into everyday practice.
Kirstie a technology news reporter at DevX. She reports on emerging technologies and startups waiting to skyrocket.
